key: cord-0746771-wkl3jyzn
authors: Houghton, Damon E.; Wysokinski, Waldemar; Casanegra, Ana I.; Padrnos, Leslie J.; Shah, Surbhi; Wysokinska, Ewa; Pruthi, Rajiv; Ashrani, Aneel; Sridharan, Meera; Baumann‐Kreuziger, Lisa; McBane, Robert; Padmanabhan, Anand
title: Risk of venous thromboembolism after COVID‐19 vaccination
date: 2022-04-20
journal: J Thromb Haemost
DOI: 10.1111/jth.15725
sha: ccdc23d41daa483aaae806ae9dec0ecd290fbccb
doc_id: 746771
cord_uid: wkl3jyzn

BACKGROUND: COVID‐19 vaccinations in the United States are effective in preventing illness and hospitalization yet concern over post‐vaccination venous thromboembolism (VTE) risk has led to vaccine hesitancy. METHODS: The aim of this study was to compare VTE rates before and after COVID‐19 vaccination. COVID‐19 vaccinated patients ≥18 years between November 1, 2020 through November 1, 2021 were analyzed using electronic medical records across the Mayo Clinic enterprise. The primary outcome was imaging confirmed acute VTE (upper or lower deep vein thrombosis or pulmonary embolism) occurring 90 days before and after the date of first vaccine dose. RESULTS: A total of 792 010 patients with at least one COVID‐19 vaccination were identified (Pfizer, n = 452 950, Moderna, n = 290 607, and Janssen [Johnson & Johnson], n = 48 453). A total of 1565 VTE events occurred in the 90 days before (n = 772) and after (n = 793) COVID‐19 vaccination. VTE post‐vaccination occurred in 326 patients receiving Moderna (0.11%, incidence rate [IR] 4.58 per 1000p‐years), 425 patients receiving Pfizer (0.09%, IR 3.84 per 1000p‐years), and 42 receiving Janssen (0.09%, IR 3.56 per 1000p‐years). Compared to the pre‐vaccination timeframe, the adjusted hazard ratio (aHR) for VTE after the Janssen vaccination was 0.97 (95% confidence interval [CI] 0.63–1.50), aHR 1.02 (95% CI 0.87–1.19) for Moderna, and aHR 1.00 (95% CI 0.87–1.15) for Pfizer. CONCLUSION: In this large cohort of COVID‐19 vaccinated patients, no increased risk for acute VTE post‐vaccination was identified for the authorized vaccines in the United States.

tion was used as the index date. This study was approved by the Mayo Clinic Institutional Review Board in Rochester, Minnesota.

For requests of original data, please contact the corresponding author.

Demographic variables including age at COVID-19 vaccination, sex, race, and zip code were extracted from electronic records. Using the cohort of COVID-19-vaccinated patients, electronic medical records were searched to identify all hospital admissions (elective or urgent/ emergent) and emergency department (ED) visits, surgeries (requiring general or regional anesthesia) within 90 days before or after the index date, and pregnancy status and delivery dates. Laboratory records were searched to identify cases of laboratory-confirmed COVID-19 infection and testing for platelet factor 4 antibodies.

International Classification of Diseases (ICD) 10 codes were used to evaluate for baseline comorbidities and to calculate a Charlson Comorbidity Index (CCI). Radiology text reports within 90 days before and after the index vaccination date were extracted (computed tomography [CT] scans of the chest and all venous Duplex ultrasounds of the upper or lower extremity).

Thromboembolic events were extracted from the electronic medical record in the 90 days before and after the index date through December 9, 2021. VTE was defined as upper or lower extremity deep vein thrombosis (DVT; proximal and distal) and pulmonary embolism (PE) and were analyzed from radiology text reports using highly accurate, previously validated natural language processing (NLP) algorithms. 1 

The time to VTE curves in the post-versus pre-vaccination timeframes for each COVID-19 vaccine are shown in Figure 1 Due to the concern for VITT in younger women, 9 the results were also stratified by sex and age (+/−60 years) and by vaccine manufacturer and there was no statistically significantly elevated risk of VTE within any of these subgroups with Janssen or Moderna vaccines. We did however observe an elevated post-vaccination VTE risk in women less than 60 with Pfizer (aHR 1.53, 95% CI 1.07-2.19) whereas men less than 60 had a lower risk of VTE (aHR 0.70, 95% CI 0.50-0.97). On further evaluation of age in quartiles, a statistically significant risk in women was only present in the lowest p-yrs respectively. We further investigated this finding by identifying women who were pregnant in the study timeframe and found there was an increased number of vaccinations around the time of delivery and women with pregnancies were much more likely to receive vaccination with the Pfizer vaccine (Table 1) . After removing these patients from the analysis, the results were no longer statistically significant (aHR 1.82, 95% CI 0.95-3.49). Within the overall group of women with current or recent pregnancies (any vaccine), the aHR for post-vaccination VTE was 6.18 (95% CI 1.26-30.2). The lower overall sample size and event rates did not allow for further analyses such as stratification based on the trimester 

Age, sex, and comorbidities were significantly different among patients receiving different vaccines ( 

This study represents the largest observational cohort to specifi- The sample size of this cohort of vaccinated patients was smaller, which limits the evaluation of an outcome as rare as VITT; however, we believe that our analysis provides additional reassurance that the Janssen vaccine does not induce a generalized hypercoagulable state and that VITT is not the "tip of the iceberg." 

Dr. Anand Padmanabhan reports financial relationships with: equity ownership (Retham Technologies), advisory board (Veralox

Recommendations for the clinical and laboratory diagnosis of vaccine-induced immune thrombotic thrombocytopenia (VITT) for SARS-CoV-2 infections: communication from the ISTH SSC Subcommittee on Platelet Immunology

Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination

Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination

Pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV-19 vaccination

Joint CDC and FDA statement on Johnson & Johnson COVID-19 vaccine

Vaccination against COVID-19: insight from arterial and venous thrombosis occurrence using data from VigiBase

Macrovascular thrombotic events in a mayo clinic enterprise-wide sample of hospitalized COVID-19-positive compared with COVID-19-negative patients

Case series of thrombosis with thrombocytopenia syndrome following COVID-19 vaccination-United States

Vaccination safety don't toss the champagne with the cork

Surveillance for adverse events after COVID-19 mRNA vaccination

Safety of the BNT162b2 mRNA Covid-19 vaccine in a nationwide setting

Risk of first venous thromboembolism in and around pregnancy: a population-based cohort study

Prenatal maternal COVID-19 vaccination and pregnancy outcomes

COVID-19 vaccination during pregnancy: coverage and safety

Interim clinical considerations for use of COVID-19 vaccines currently approved or authorized in the United States

CDC_AA_refVa l=https %3A%2F%2Fwww.cdc.gov%2Fvac cines %2Fcov id-19%2Finf o-byprodu ct%2Fcli nical -consi derat ions.html#consi derat ions-Janssen

Thrombosis with thrombocytopenia syndrome (also termed Vaccine-induced Thrombotic Thrombocytopenia)

COVID-19 vaccine use following thorough safety review

Risk of venous thromboembolism after COVID-19 vaccination